Biomarker Deals: Terms, Value and Trends (2008-2018) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 17, 2018--The “Biomarker Deals: Terms, Value and Trends, 2008-2018” report has been added to ResearchAndMarkets.com’s offering.
This report represents a current and important business tool to evaluate terms and conditions of licensing, acquisitions and partnerships deals in the biomarker sector. The geographic scope of this study covers the U.S. and companies worldwide. The report identifies the main elements in licensing, acquisitions and partnership deals in the biomarker industry.
The report includes:An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including detailed analysis of deals structure and their potential values Information about significant players in this field of study, trends and obstacles, and other information affecting biomarker market development Review of business terms and conditions of deals in the biomarker market, with focus on major trends in biomarker deal making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities Essential information to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products. Identification of the main elements in licensing, acquisitions and partnership deals in the biomarker industry Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis et al. Details of various types of biomarkers deals and milestone payments and their value in different deals Examination of competitive landscape and detailed profiles of major companies developing biomarkers, including bioMerieux SA, IntegraGen SA, MDxHealth, Myriad Genetics, Protagen AG and Qiagen
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology BackgroundBiomarker Definition and Classification Biomarker Applications Biomarker Identification and Detection Technologies Steps in Biomarker Development Biomarker Market Analysis and Evaluation Global Biomarker Market Value and its Segmentation Oncology-Related Biomarkers Sector Cardiovascular Diseases Biomarker Sector Neurological Disorders and Other Diseases Biomarkers Sector Market Participants in the Biomarkers Space
Chapter 4 Biomarkers Market - Licensing, Acquisitions, Collaborations Deal AnalysisLicensing Deals in the Biomarkers Market, 2008-2018 Licensing Deal Definition and General Structure Valuation and Payment Structure Analysis of Licensing Deals in the Biomarkers Market, 2008-2018 Acquisition Deals in the Biomarkers Market, 2008-2018 Acquisition Deal Definition and General Structure Analysis of Acquisition Deals in the Biomarkers Market, 2008-2018 Partnerships/Collaboration Deals in the Biomarkers Market, 2008-2018 Collaboration Deal Definition and General Structure Analysis of Partnership/collaboration Deals in the Biomarkers Market, 2008-2018 Analysis of Different Aspects of Licensing, Acquisition and Collaboration Deals in the Biomarkers Market Analysis of Licensing Deals Structure in the Biomarkers Market, 2008-2018 Analysis of Acquisition Deals Structure in the Biomarkers Market, 2008-2018 Analysis of Collaboration Deals Structure in the Biomarkers Market, 2008-2018 Biomarker Market Participants Active in Licensing, Acquisitions and Partnership/Collaboration Deals, 2008-2018 Qiagen bioMerieux MDxHealth Myriad Genetics
Chapter 5 Impact of Other Markets and Clinical Trials on Licensing, Acquisition and Collaborations in the Biomarkers MarketCancer Diagnostics as Market Potential for Exosome-Based Diagnostics Product Development Prostate Cancer as Potential for Biomarker Development Breast Cancer as Potential for Biomarker Development Bladder Cancer as Potential for Biomarker Development Ovarian Cancer as Potential for Biomarker Development Lung Cancer as Potential for Biomarker Development CNS Disorders and Neurodegeneration Diseases as Market Potential for Biomarker Development Cardiovascular Diseases as Market Potential for Biomarker Development Organ Transplantation as Market Potential for Biomarker Development in Immune Disorders Clinical Trials as Indicator for Biomarker Market Development
Chapter 6 Patent Review/New Developments
Chapter 7 Market Summary
Chapter 8 Company ProfilesbioMerieux S.A. Integragen S.A. MDX Health Myriad Genetics Protagen AG Qiagen
For more information about this report visit https://www.researchandmarkets.com/research/r26rsq/biomarker_deals?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005721/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/17/2018 01:38 PM/DISC: 12/17/2018 01:38 PM